Satsuma Pharmaceuticals, Inc. (STSA)

Satsuma Pharmaceuticals, Inc. (STSA) — VMCI valuation read

Headline read on STSA: VMCI of 41/100 versus a Healthcare sector median of 50. The 9-point below-median position is what makes Satsuma Pharmaceuticals, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on STSA: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on STSA: value (STSA trades at 23.0x earnings, 28% above the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -0.7x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

STSA fell 3.7% over the trailing 7 days, with a -7.5% read on a 30-day basis.